Target

NKGen Biotech Advances Alzheimer’s Treatment with SNK01: First Patient Dosed in Phase 1/2a Trial

December 29, 2023 - NKGen Biotech, Inc. (Nasdaq: NKGN) is making strides in Alzheimer's disease (AD) treatment with the dosing of the first patient in its Phase 1/2a trial for SNK01, an autologous natural killer (NK) cell therapy. The innovative product, designed for moderate AD, has demonstrated promising results in neuroinflammation and cognitive function during its Phase 1 safety trial. Key Points: SNK01 Efficacy: NKGen's SNK01, a cryopreserved autologous NK cell therapy, showed improvement in neuroinflammation and cognitive function in the Phase 1 dose-escalation safety trial. The therapy boasts enhanced

GPO Plus, Inc. (GPOX) Achieves Record Revenues with 25% Quarterly Growth

December 18, 2023 - GPO Plus, Inc. (OTCQB: GPOX), a prominent distribution and manufacturing company specializing in consumer products for convenience stores, gas stations, and specialty retailers, has reported impressive Q2 financial results. The company's gross revenue for the quarter ending October 31, 2023, reached a record $1.21 million, marking a substantial 25% increase from the previous quarter ending July 31, 2023, which reported $970,735 in gross revenues. Key Highlights: Quarterly Revenue Surge: GPOX achieved a remarkable 25% surge in top-line revenue, reaching $1.213 million in the second quarter, up

From Dominance to Compliance

Last Tuesday saw Binance settle its long-running legal disputes with several U.S. government agencies, including the Department of Justice (DoJ), the Department of the Treasury’s Financial Crimes Enforcement Network (FinCEN), the Office of Foreign Assets Control (OFAC), and the U.S. Commodity Futures Trading Commission (CFTC). However, they failed to reach an agreement with the Securities and Exchange Commission (SEC) regarding their pending charges. As part of the settlement, Binance has agreed to pay an eye-popping fine of $4.3 billion. Furthermore, Changpeng Zhao (CZ), the CEO of Binance, will step down

NEW APPEAL TO PROVIDE SUPPORT TO THOUSANDS OF ISRAELI CITIZENS FOLLOWING HAMAS ASSAULT

  Tel Aviv, New York & London; October 19, 2023: In the wake of the recent catastrophic and unprecedented attack that was launched at Israel by Hamas on and beyond October 7, Ahavat Yisroel Humanity Inc. has launched an urgent fundraising appeal in order to provide much-needed support and supplies to the thousands of Israeli citizens affected. The Israel Now, Israel Forever appeal is seeking donations to provide the many affected citizens with food, shelter, and urgent suppliers. The donations will be shared among four established and experienced relief organisations

The Tightrope of Regulation

In a significant move at the recent G20 meeting in India, the International Monetary Fund (IMF) and the Financial Stability Board (FSB) released a joint paper outlining a framework for the global regulation of cryptocurrencies. While the proposals mostly tread familiar territory, what’s new is their conviction in crypto’s unstoppable growth and success. A flurry of optimism greeted the G20’s endorsement of the report because it advocates that countries don’t ban crypto. Hidden in its text, however, are some worrying signs. For example, on the first page, they state, “Widespread

Coya Therapeutics Reports Additional Biomarker and Imaging Data Showing Decrease in Neuroinflammation with COYA 301 in Alzheimer’s Disease.

Highlights Coya reports new data illustrating that administration of COYA 301 (low dose Interleukin-2 (IL-2)) in an open- label study in 8 patients with mild to moderate AD (COYA 301 Trial) resulted in a statistically significant reduction in the expression of three well characterized proinflammatory cytokines -- Tumor Necrosis Factor alpha (TNF-α), Interleukin 6 (IL-6), and Interleukin 1- Beta (IL-1β) -- which correlated with lack of cognitive decline of the patients over the course of the study. TNF-α is one of the main inflammatory cytokines involved in initiating and propagating

Verofax to raise US$750,000 on Beban Crowdfunding Platform

- Offering GCC retail investors interactive access to private equity investment opportunities BAHRAIN, Mar 5, 2023 - (ACN Newswire) - Verofax, the leader in brand marketing and AI-powered solutions for enterprise, was featured on Beban 2 (Episode 9, Mar 1, 2023), the hit entrepreneur & investment-themed reality TV program airing on Bahrain TV, Alrai TV and Dubai TV, as well as Shahid, the region's largest video-on-demand platform. Wassim Merheby, CEO & Co-Founder, and Jamil Zablah, CMO & Co-Founder, Veromax, a product winning SaaS provider helping brands achieve growth by turning offline products interactive for

Blockchain Moon acquires DLTx ASA

A year after its initial public offering, a Jacksonville-based blank check company formed to seek acquisitions has found its target. Blockchain Moon Acquisition Corp. announced an agreement Oct. 15 to acquire DLTx ASA, an Oslo, Norway-based company developing blockchain technology. As its name implies, Blockchain Moon was formed to find businesses in that industry. “DLTx is a tech company run by decentralists who believe in the new economy that is powered by cryptographic digital assets. The DLTx team has been at the forefront of developing and launching of several of

DLTx Invests in Blockchain Moon Acquisition Corp.

DLTx has completed an investment in Blockchain Moon Acquisition Corp, a company incorporated under the laws of Delaware. As communicated in the Q2 report, DLTx was one of the early investors in a SPAC (Special-purpose Acquisition Company) focusing on distributed ledger technologies. DLTx invested $653,350 USD in Blockchain Moon Acquisition Corp. through Jupiter Sponsor LLC, a company which we hold the units of BMAC through. The investment equates to 406,500 shares at the initial public offering (IPO). In the IPO, shares will be valued at $10 USD each. Of the

Mainnet Update

One of the silver linings, indeed perhaps the only silver lining, from the bear market disasters of the past few months has been the opportunity it afforded the Paribus development team to deploy our MVP via testnet. Even this however wasn’t free from challenges, so in this article, we dive a little deeper into what the next few weeks and months hold for Paribus. Our primary focus is to be able to transition from the testnet to the mainnet, but at the same time, we’ve also been limited by some